Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.63 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.63 |
| ▸ | RXRA | P19793 | 3/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 13/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679052 | 0.94 | NR1H2 (0.62) | NR1H2NR1H3RXRAAKR1C3AKR1C2 | |
| SCHEMBL1679269 | 0.93 | NR1H2 (0.61) | NR1H2NR1H3RXRAAKR1C3AKR1C2 | |
| SCHEMBL1678560 | 0.92 | NR1H2 (0.60) | NR1H2NR1H3RXRAAKR1C3AKR1C2 | |
| SCHEMBL1678042 | 0.92 | NR1H2 (0.60) | NR1H2NR1H3RXRAAKR1C3AKR1C2 | |
| SCHEMBL1679165 | 0.91 | NR1H2 (0.59) | NR1H2NR1H3RXRAAKR1C3AKR1C2 | |
| SCHEMBL1678343 | 0.91 | NR1H2 (0.72) | NR1H2NR1H3RXRAAKR1C3AKR1C2 | |
| SCHEMBL1678777 | 0.90 | NR1H2 (0.58) | NR1H2NR1H3RXRAAKR1C3AKR1C2 | |
| SCHEMBL1678759 | 0.90 | NR1H2 (0.58) | NR1H2NR1H3RXRAAKR1C3AKR1C2 | |
| SCHEMBL1678473 | 0.86 | NR1H2 (0.63) | NR1H2NR1H3RXRAAKR1C3AKR1C2 | |
| SCHEMBL1679624 | 0.85 | NR1H2 (0.62) | NR1H2NR1H3RXRAAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | NR1H2 1/4885NR1H3 2/4885RXRA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.